NEW YORK and NEW ORLEANS, Feb. 17, 2026 (GLOBE NEWSWIRE) -- (“KSF”) and KSF partner, former Attorney General of Louisiana, Charles C. Foti, Jr., notifies ...

Attorneys at Sidley Austin LLP examine the issue of drug price reporting rules under Medicaid and enforcement risks under the False Claims Act.

Q VYJUVEK revenue and $730.3 million since U.S. launchFDA granted RMAT to KB707 for the treatment of advanced NSCLC and Fast ...

Levi & Korsinsky, LLP notifies investors in Ultragenyx Pharmaceutical Inc. ("Ultragenyx" or the "Company") (NASDAQ: RARE) of a class action securities lawsuit.

A computational biology company that started in space tech is looking to change how biopharma finds disease targets by ...

It is nearly eight years since healthcare and biotech investor Sam Isaly abruptly stepped down from OrbiMed, the managers of the Worldwide Healthcare Trust (LSE: WWH). In the 22 years in which he was ...

RBC Capital Markets believes that recent January data on Biohaven's epilepsy drug has helped reduced uncertainty around the treatment. The bank upgraded the biopharmaceutical stock to outperform from ...

Biotech valuations are lower relative to other sectors after a decade of stagnation. Denali Therapeutics fell 75% over five years despite its patented blood-brain barrier transport platform. Xenon ...

Arthur Herman’s op-ed, “America Is the Sole Superpower Again,” (Jan. 15) asserts that China is “sliding into a distant second place” in the battle for economic, military and technological supremacy.

Saudi Arabia is orchestrating an ambitious industrial transformation. Historically defined by oil, the Gulf state is investing in vaccines, biomanufacturing, and genomics with the aim of being a ...

2025 proved a turning point year for the biotech industry, albeit one wrought with contradiction. The post-COVID slump experienced by the industry seemed due to continue, with the sweeping cuts to the ...

Biotech IPOs hit lowest level in over a decade in 2025 Investors focus on biotechs with mature pipelines and positive trial data Lower interest rates and capital inflows expected to boost sector Jan ...